MX371295B - Formación de imágenes por irm de placas amiloides usando liposomas. - Google Patents
Formación de imágenes por irm de placas amiloides usando liposomas.Info
- Publication number
- MX371295B MX371295B MX2017004695A MX2017004695A MX371295B MX 371295 B MX371295 B MX 371295B MX 2017004695 A MX2017004695 A MX 2017004695A MX 2017004695 A MX2017004695 A MX 2017004695A MX 371295 B MX371295 B MX 371295B
- Authority
- MX
- Mexico
- Prior art keywords
- liposomes
- mri imaging
- amyloid plaque
- imaging
- aromatic
- Prior art date
Links
- 238000003384 imaging method Methods 0.000 title abstract 3
- 239000002502 liposome Substances 0.000 title abstract 2
- 208000037259 Amyloid Plaque Diseases 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 150000001491 aromatic compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
- A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polyethers (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462061514P | 2014-10-08 | 2014-10-08 | |
| US201562111057P | 2015-02-02 | 2015-02-02 | |
| PCT/US2015/054732 WO2016057812A1 (en) | 2014-10-08 | 2015-10-08 | Mri imaging of amyloid plaque using liposomes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017004695A MX2017004695A (es) | 2018-01-24 |
| MX371295B true MX371295B (es) | 2020-01-24 |
Family
ID=55653789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004695A MX371295B (es) | 2014-10-08 | 2015-10-08 | Formación de imágenes por irm de placas amiloides usando liposomas. |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US9744251B2 (https=) |
| EP (3) | EP3204051B1 (https=) |
| JP (1) | JP6505235B2 (https=) |
| KR (1) | KR102409017B1 (https=) |
| CN (1) | CN107106708B (https=) |
| AU (2) | AU2015330824A1 (https=) |
| CA (1) | CA2963941C (https=) |
| ES (2) | ES2743704T3 (https=) |
| MX (1) | MX371295B (https=) |
| WO (1) | WO2016057812A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102035187B1 (ko) | 2011-04-06 | 2019-11-08 | 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 지질-기반 나노입자들 |
| MX366972B (es) | 2012-01-20 | 2019-08-01 | Ananth Annapragada | Metodos y composiciones para caracterizar imagenes medicas en forma objetiva. |
| AU2015330824A1 (en) | 2014-10-08 | 2017-05-25 | Ananth Annapragada | MRI imaging of amyloid plaque using liposomes |
| KR102472003B1 (ko) | 2016-07-22 | 2022-11-29 | 에이씨 이뮨 에스에이 | 타우 단백질 응집체를 이미징하기 위한 화합물 |
| EP3487545A1 (en) | 2016-07-22 | 2019-05-29 | AC Immune S.A. | Compounds for imaging tau protein aggregates |
| US11052162B2 (en) | 2016-09-16 | 2021-07-06 | Texas Children's Hospital | Liposomal gadolinium (GD) contrast agent “NMRX” for T1-MRI |
| EP3548002B1 (en) * | 2016-11-30 | 2025-04-30 | Texas Children's Hospital | Hydrophilic fluorinated molecules for liposomal 19f mri probes with unique mr signatures |
| WO2019145291A1 (en) | 2018-01-24 | 2019-08-01 | Ac Immune Sa | Gamma-carboline compounds for the detection of tau aggregates |
| WO2019145292A1 (en) | 2018-01-24 | 2019-08-01 | Ac Immune Sa | Azacarboline compounds for the detection of tau aggregates |
| EP3773500A4 (en) * | 2018-03-29 | 2022-03-16 | Microvascular Therapeutics LLC | COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE |
| IL279219B2 (en) | 2018-06-08 | 2024-08-01 | Ac Immune Sa | Novel compounds for diagnosis |
| US20200261605A1 (en) * | 2019-01-24 | 2020-08-20 | Alzeca Biosciences, LLC | Functionalized liposomes for imaging misfolded proteins |
| JP7702381B2 (ja) * | 2019-07-08 | 2025-07-03 | アルゼカ バイオサイエンシズ、エルエルシー | タウ病理のためのターゲティングリガンド |
| US11614451B2 (en) | 2019-07-08 | 2023-03-28 | Alzeca Biosciences, LLC | Targeting ligands for tau pathology |
| CN115916263B (zh) * | 2020-01-29 | 2025-10-03 | 德克萨斯儿童医院 | 用于淀粉样蛋白沉积mri的靶向对比剂 |
| US11779664B2 (en) | 2020-02-12 | 2023-10-10 | Texas Children's Hospital | Targeted contrast agents for MRI of alpha-synuclein deposition |
| EP4103239A4 (en) * | 2020-02-12 | 2024-03-20 | Texas Children's Hospital | Targeted contrast agents for mri of alpha-synuclein deposition |
| CN115970009A (zh) * | 2023-02-08 | 2023-04-18 | 丽水市中心医院 | Vhpk多肽修饰的荧光纳米脂质体给药系统、其制备方法及应用 |
| CN116869938A (zh) * | 2023-07-26 | 2023-10-13 | 安徽医科大学 | 一种1,2,4-噁二唑-吡啶脂质体及其制备方法和应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204085A (en) | 1985-01-08 | 1993-04-20 | Mallinckrodt Medical, Inc. | Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents |
| WO1995026205A1 (en) | 1994-03-28 | 1995-10-05 | Nycomed Imaging A/S | Liposomes |
| US6071532A (en) * | 1996-10-15 | 2000-06-06 | Emory University | Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof |
| DE60017787T2 (de) | 1999-11-30 | 2006-01-05 | ARIZONA BOARD OF REGENTS, on behalf of THE UNIVERSITY OF ARIZONA, Tucson | Strahlung-sensitive liposomen |
| WO2002028441A2 (en) | 2000-10-04 | 2002-04-11 | California Institute Of Technology | Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits |
| US6821504B2 (en) | 2001-05-23 | 2004-11-23 | New York University | Detection of alzheimer's amyloid by magnetic resonance imaging |
| EP1480691A4 (en) | 2002-03-05 | 2007-11-28 | Univ State Cleveland | AGGLOMERATED PARTICLES FOR THE DISPOSAL OF A MEDICINAL PRODUCT IN AEROSOL FORM |
| EP1641742A4 (en) | 2003-05-01 | 2006-11-29 | Nst Neurosurvival Technologies | COMPOUNDS BINDING SELECTIVELY TO MEMBRANES OF APOPTOTIC CELLS |
| US7208174B2 (en) | 2003-12-18 | 2007-04-24 | Hoffmann-La Roche Inc. | Liposome compositions |
| US20100031378A1 (en) | 2008-08-04 | 2010-02-04 | Edwards Joel A | Novel gene disruptions, compositions and methods relating thereto |
| US8357351B2 (en) | 2004-04-21 | 2013-01-22 | Ananth Annapragada | Nano-scale contrast agents and methods of use |
| US7713517B2 (en) | 2004-04-21 | 2010-05-11 | Marval Biosciences, Inc. | Compositions and methods for enhancing contrast in imaging |
| JP2008513533A (ja) | 2004-09-23 | 2008-05-01 | ゲルベ | Ｃｅｓｔイメージング用の造影剤封入システム |
| CA2626005A1 (en) | 2005-10-13 | 2007-10-25 | Waratah Pharmaceuticals Inc. | Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence |
| US20070160658A1 (en) | 2005-10-20 | 2007-07-12 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
| US20090123047A1 (en) | 2007-03-21 | 2009-05-14 | Yfantis Spyros A | Method and system for characterizing prostate images |
| EP1982733A1 (en) | 2007-04-17 | 2008-10-22 | Bayer Schering Pharma Aktiengesellschaft | Use of a contrast agent for magnetic resonance imaging of endoleaks |
| WO2008134618A2 (en) | 2007-04-27 | 2008-11-06 | The General Hospital Corporation | Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders |
| EP2182924A1 (en) | 2007-07-26 | 2010-05-12 | Nanoscan Imaging, Llc | Methods for imaging using improved nanoparticulate contrast agents |
| JP2011506325A (ja) | 2007-12-05 | 2011-03-03 | マーバル バイオサイエンシーズ インコーポレイテッド | ナノスケールのコントラスト剤及びその使用方法 |
| CA2711503A1 (en) * | 2008-01-08 | 2009-07-16 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
| ITMI20081052A1 (it) | 2008-06-10 | 2009-12-11 | Univ Milano Bicocca | Liposomi in grado di legare efficacemente il peptide beta-amiloide |
| US20090311191A1 (en) | 2008-06-13 | 2009-12-17 | Ananth Annapragada | Imaging of atherosclerotic plaques using liposomal imaging agents |
| WO2010017094A2 (en) | 2008-07-31 | 2010-02-11 | The General Hospital Corporation | CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| WO2010107990A1 (en) | 2009-03-19 | 2010-09-23 | Marval Biosciences, Inc. | Compositions and methods for enhancing contrast in imaging |
| EP2501696B1 (en) | 2009-10-15 | 2016-12-28 | Guerbet | Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
| JP5746334B2 (ja) * | 2010-06-16 | 2015-07-08 | シマベイ セラピューティクス， インコーポレーテッド | Ｇｐｒ１２０受容体作動薬及びその使用 |
| CN103429226A (zh) | 2011-03-02 | 2013-12-04 | 森苏林公司 | 囊泡组合物 |
| KR102035187B1 (ko) | 2011-04-06 | 2019-11-08 | 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 지질-기반 나노입자들 |
| GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| MX366972B (es) | 2012-01-20 | 2019-08-01 | Ananth Annapragada | Metodos y composiciones para caracterizar imagenes medicas en forma objetiva. |
| WO2013164763A2 (en) | 2012-04-30 | 2013-11-07 | Innovative Health Diagnostics | A biological complex specific for alzheimer's disease detection in vitro and use thereof |
| MX2015011677A (es) * | 2013-03-14 | 2016-07-08 | Celtaxsys Inc | Inhibidores de leucotrieno a4 hidrolasa. |
| AU2015330824A1 (en) | 2014-10-08 | 2017-05-25 | Ananth Annapragada | MRI imaging of amyloid plaque using liposomes |
-
2015
- 2015-10-08 AU AU2015330824A patent/AU2015330824A1/en not_active Abandoned
- 2015-10-08 US US14/878,745 patent/US9744251B2/en active Active
- 2015-10-08 CA CA2963941A patent/CA2963941C/en active Active
- 2015-10-08 WO PCT/US2015/054732 patent/WO2016057812A1/en not_active Ceased
- 2015-10-08 KR KR1020177012354A patent/KR102409017B1/ko active Active
- 2015-10-08 ES ES15849750T patent/ES2743704T3/es active Active
- 2015-10-08 CN CN201580066712.6A patent/CN107106708B/zh active Active
- 2015-10-08 JP JP2017538918A patent/JP6505235B2/ja active Active
- 2015-10-08 EP EP15849750.3A patent/EP3204051B1/en active Active
- 2015-10-08 ES ES22152987T patent/ES3032054T3/es active Active
- 2015-10-08 EP EP19172751.0A patent/EP3542828A1/en not_active Withdrawn
- 2015-10-08 EP EP22152987.8A patent/EP4035688B1/en active Active
- 2015-10-08 MX MX2017004695A patent/MX371295B/es active IP Right Grant
-
2016
- 2016-12-01 US US15/366,667 patent/US10537649B2/en active Active
-
2019
- 2019-11-08 US US16/677,751 patent/US20200069820A1/en not_active Abandoned
-
2020
- 2020-02-14 US US16/791,068 patent/US11141495B2/en active Active
-
2021
- 2021-05-25 AU AU2021203388A patent/AU2021203388B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2743704T3 (es) | 2020-02-20 |
| AU2015330824A1 (en) | 2017-05-25 |
| US20200179540A1 (en) | 2020-06-11 |
| CA2963941A1 (en) | 2016-04-14 |
| JP6505235B2 (ja) | 2019-04-24 |
| EP3542828A1 (en) | 2019-09-25 |
| EP3204051B1 (en) | 2019-05-29 |
| US20170080111A1 (en) | 2017-03-23 |
| EP4035688C0 (en) | 2025-03-26 |
| CN107106708B (zh) | 2021-06-18 |
| US20160101197A1 (en) | 2016-04-14 |
| KR20170103748A (ko) | 2017-09-13 |
| JP2017532378A (ja) | 2017-11-02 |
| CN107106708A (zh) | 2017-08-29 |
| HK1243335A1 (zh) | 2018-07-13 |
| ES3032054T3 (en) | 2025-07-15 |
| EP3204051A4 (en) | 2018-06-27 |
| US11141495B2 (en) | 2021-10-12 |
| EP3204051A1 (en) | 2017-08-16 |
| MX2017004695A (es) | 2018-01-24 |
| US10537649B2 (en) | 2020-01-21 |
| CA2963941C (en) | 2023-08-01 |
| WO2016057812A1 (en) | 2016-04-14 |
| KR102409017B1 (ko) | 2022-06-16 |
| BR112017007238A2 (pt) | 2018-01-16 |
| EP4035688A1 (en) | 2022-08-03 |
| US9744251B2 (en) | 2017-08-29 |
| AU2021203388A1 (en) | 2021-06-24 |
| EP4035688B1 (en) | 2025-03-26 |
| AU2021203388B2 (en) | 2024-05-30 |
| US20200069820A1 (en) | 2020-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017004695A (es) | Formación de imágenes por irm de placas amiloides usando liposomas. | |
| IL282995B1 (en) | Lipid nanoparticle formulations | |
| EP3268086A4 (en) | Lsd for the treatment of alzheimer's disease | |
| MX2017004473A (es) | Formulaciones de betalactamasa y usos de las mismas. | |
| ZA201807871B (en) | Methods for making ultrasound contrast agents | |
| MX357227B (es) | Nanoparticulas basadas en lipidos. | |
| MA46621A (fr) | Traitements combinés comprenant l'administration d'imidazopyrazinones | |
| WO2016094374A8 (en) | Compositions and methods for treatment of friedreich's ataxia | |
| EP3399965A4 (en) | PROLIPOSOMAL TESTOSTERONE ANDECANOATE FORMULATIONS | |
| WO2016183223A3 (en) | Targeted protein contrast agents, methods of making, and uses thereof | |
| PL3285755T3 (pl) | Chlorowodorek kreatyny do leczenia choroby Huntingtona | |
| MX2016003725A (es) | Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau. | |
| IL264040A (en) | An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients | |
| SG11201708003WA (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease | |
| EP3634979A4 (en) | COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS | |
| JP2015208317A5 (https=) | ||
| EP3634385A4 (en) | LIPOSOME PREPARATION PROCESSES INCLUDING MEDICINAL PRODUCTS | |
| GB201615913D0 (en) | Angler's seat box | |
| EP3302579A4 (en) | Iron stabilized micelles as magnetic contrast agents | |
| IN2013MU02813A (https=) | ||
| HK40050182A (en) | Lipid nanoparticle formulations | |
| HK40050187A (en) | Lipid nanoparticle formulations | |
| EM34627950001S (fi) | Kampaamotuolit | |
| GB201600833D0 (en) | The procedure for restoration of metabolism and new formula of 15 proteins | |
| HK40024508A (en) | Compositions and methods for treating alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |